Irhythm Technologies Inc. logo

Irhythm Technologies Inc. (I25)

Market Closed
12 Jun, 06:09
126. 00
-2
-1.56%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-3.38 Eps
128
Previous Close
Day Range
126 126
Year Range
52 130
Earnings results expected in 48 days

Summary

I25 closed today lower at €126, a decrease of 1.56% from yesterday's close, completing a monthly increase of 30.57% or €29.5. Over the past 12 months, I25 stock gained 45.66%.
I25 is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track I25 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

I25 Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.

Accessnewswire | 9 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.

Accessnewswire | 2 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.

Accessnewswire | 4 days ago

Irhythm Technologies Inc. Dividends

I25 is not paying dividends to its shareholders.

Irhythm Technologies Inc. Earnings

30 Jul 2025 (48 Days) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
20 Feb 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
I25 is not paying dividends to its shareholders.
30 Jul 2025 (48 Days) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
20 Feb 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS

Irhythm Technologies Inc. (I25) FAQ

What is the stock price today?

The current price is €126.00.

On which exchange is it traded?

Irhythm Technologies Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is I25.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Irhythm Technologies Inc. ever had a stock split?

No, there has never been a stock split.

Irhythm Technologies Inc. Profile

Medical - Devices Industry
Healthcare Sector
Mr. Quentin S. Blackford CEO
XSTU Exchange
US4500561067 ISIN
US Country
2,000 Employees
- Last Dividend
- Last Split
20 Oct 2016 IPO Date

Overview

iRhythm Technologies, Inc. is a pioneering digital healthcare organization primarily focused on the design, development, and deployment of innovative device-based solutions aimed at the ambulatory cardiac monitoring sector within the United States. Leveraging advanced technology, the company's mission revolves around facilitating the diagnosis of arrhythmias—irregular heartbeats that can lead to serious health issues. The essence of iRhythm's offering is encapsulated in its commitment to enhancing cardiac care through digital innovation, where it brings a unique blend of clinical expertise and technological prowess. Established in 2006 and based in San Francisco, California, the company has established itself as a key player in the realm of cardiac healthcare by offering groundbreaking services that significantly improve patient outcomes. Additionally, iRhythm Technologies maintains a collaborative development agreement with Verily Life Sciences LLC and Verity Ireland Limited, focusing on the creation of cutting-edge atrial fibrillation screening, detection, and monitoring products, thereby broadening its impact on patients' lives.

Products and Services

  • Zio services
  • iRhythm provides the Zio services as an innovative ambulatory monitoring solution that caters to the needs of patients requiring long-term, short-term continuous monitoring, and mobile cardiac telemetry monitoring services. The essence of Zio services lies in their ability to offer comprehensive cardiac monitoring, thereby facilitating timely and accurate diagnosis of arrhythmias. Through Zio services, patients benefit from a sophisticated monitoring approach that combines convenience with clinical efficacy.

  • Zio Monitor System
  • At the heart of iRhythm's product lineup is the Zio Monitor System, a state-of-the-art remote electrocardiogram (ECG) monitoring system that includes a wearable patch ECG monitor. Capable of recording the electrical signals from the heart continuously for up to 14 days, this system exemplifies the seamless integration of technology and healthcare. In conjunction with the Zio ECG Utilization Software System, it supports the comprehensive capture and analysis of ECG data, including the identification of specific arrhythmia events. The system is prescription-only, emphasizing its role as a sophisticated diagnostic tool in the hands of healthcare professionals.

  • Zio XT System
  • The Zio XT System represents the previous generation of the Zio Monitor System, maintaining its role as a vital tool for remote ECG monitoring. Also designed to be worn for up to 14 days, the Zio XT patch continuously records the heart's electrical activity, offering a blend of reliability and convenience for patients. As a prescription-only system, it underscores iRhythm's commitment to delivering professional-grade cardiac monitoring solutions.

  • Zio AT System
  • Last but not least, the Zio AT System extends the capabilities of remote ECG monitoring with its innovative design. Similar to its predecessors, it features a patch that records the heart's electrical signals continuously for up to 14 days. Unique to the Zio AT system, however, is the inclusion of the Zio AT wireless gateway. This addition enhances connectivity between the Zio AT patch and the ZEUS System during the patient wear period, ensuring real-time data transmission and analysis. This system is also prescription-only, providing an advanced tool for healthcare providers in the management and diagnosis of cardiac conditions.

Contact Information

Address: 699 8th Street
Phone: 415 632 5700